Skip to content

Optimization of VIM Targeting in Essential Tremor Surgery

Optimization of VIM Targeting in Essential Tremor Surgery

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03760406
Acronym
Opti-VIM
Enrollment
22
Registered
2018-11-30
Start date
2019-03-18
Completion date
2023-08-29
Last updated
2026-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Tremor

Keywords

Essential Tremor, Deep brain stimulation, Ventro-intermediate nucleus of the thalamus, Targeting, Asleep surgery

Brief summary

Deep brain stimulation (DBS) for essential tremor is based on the intermedius ventralis nucleus of the thalamus (VIM) stimulation. This structure is however very difficult to target, as it remains invisible on imaging. The current procedure based on awake surgery with clinical and electrophysiological testings has several limitations that lead us to develop a probabilistic model to locate precisely the target. This study aims to show that asleep DBS surgery based on this new targeting method leads to at least the same clinical results than the classical procedure.

Detailed description

The intermedius ventralis nucleus of the thalamus (VIM), which represents the target for deep brain stimulation (DBS) in essential tremor, still remains invisible on 1,5 tesla MRI (the only magnetic field available for stereotactic surgery). The target coordinates currently used are based on stereotactic atlases or mean coordinates from retrospective series. They are so imprecise that intra-operative clinical testing and micro-electrode recordings are mandatory to locate the exact position of the VIM. This procedure is long lasting, requires that the patient is awake, and increases the risk of intracerebral haemorrhage and nosocomial infections. Furthermore, some patients are not improved despite a DBS lead implanted in the electrophysiologically and clinically defined target. To overcome these limitations, investigators developed a probabilistic model based on data extracted from imaging of patients with particularly good outcomes after DBS surgery. This machine-learning model allows calculating to coordinates of the VIM according to the position of radio-anatomical landmarks with a mean precision of 1,65mm. The aim of this study is to validate this new targeting method on a prospective cohort of patients. DBS surgery will be performed under general anaesthesia, without intra-operative clinical and electrophysiological testing, with a surgical robot and under CT-scan guidance (O-Arm ©). Neurostimulation device programming will be performed as usual. Patients' tremor and quality of life will be evaluated pre and post-operatively at 3 months, according to the Fahn-Tolosa-Marin (FTM) scale and with an accelerometry recording (for tremor) and with the mPDQ-39 scale for quality of life. Surgical complications and side effects related to neurostimulation will be gathered all along the follow-up.

Interventions

PROCEDUREOpti-VIM targeting in DBS surgery

DBS surgery will be performed under general anaesthesia, without intra-operative clinical and electrophysiological testing, with a surgical robot and under CT-scan guidance (O-Arm ©). The VIM coordinates will be calculated with the probabilistic model that have been developed.

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Severe essential tremor despite the optimal medical management * Age between 18 and 75 years * Normal MRI scan * Mattis Dementia Rating Scale (MDRS) score ≥ 130 * Affiliation to the social security * Signed informed consent

Exclusion criteria

* Depression (Beck Depression Inventory scale \> 20) * Contra-indication to surgery or general anesthesia * Cerebral atrophy on MRI scan * Pregnant or breastfeeding women

Design outcomes

Primary

MeasureTime frameDescription
Change of Fahn-Tolosa-Marin (FTM) scale scoreBefore and 3 month after DBS surgeryScale global range : min=0 / max=160 Higher values represent worse tremor

Secondary

MeasureTime frameDescription
Accelerometry recordings : spectral analysisBefore and 3 month after DBS surgeryAccelerometry recordings at the pre-inclusion visit and at 3 months after surgery in ON and OFF-stimulation conditions with spectral analysis.
Accelerometry recordings : calculation of the total accelerometry powerBefore and 3 month after DBS surgeryAccelerometry recordings at the pre-inclusion visit and at 3 months after surgery in ON and OFF-stimulation conditions with calculation of the total accelerometry power.
Surgical complicationsUp to 3 month after DBS surgeryOnset of infection, hematoma or seizure
Device complications and dysfunctionUp to 3 month after DBS surgeryrupture or displacement of electrode, pain at the stimulation box implantation site or along the subcutaneous cable if they require further intervention, infection.
Neurostimulation-related side effectsUp to 3 month after DBS surgeryOnset of dysarthria and ataxia assessed by the items 1 to 4 of the Scale for Assessment and Rating of Ataxia (SARA), ataxia assessed by a posturometry analysis, paresthesia, muscular contractions
Quality of life: change of modified Parkinson's Disease Questionnaire-39 (mPDQ-39) scale scoreBefore and 3 month after DBS surgeryAdaptation of Parkinson's Disease Questionnaire-39 to essential tremor Scale global range : min=0 / max=156 Higher values represent worse Quality of life
Coordinates of active contacts3 month after DBS surgeryCoordinates of active contacts (i.e; the contact with the best effect on tremor without side effects) These coordinates (x, y, z) are obtained by merging the images of the 3-month postoperative scanner with the images of the preoperative MRI.

Countries

France

Contacts

STUDY_CHAIRAntoine BENARD, MD

USMR CHU de Bordeaux

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 3, 2026